Gossamer Bio Announces Pricing of Initial Public Offering
February 07 2019 - 6:17PM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced the pricing
of its initial public offering of 17,250,000 shares of common stock
at a public offering price of $16.00 per share. The
shares are expected to begin trading on the Nasdaq Global Select
Market on February 8, 2019 under the ticker symbol
“GOSS.” All of the shares are being offered by Gossamer Bio.
The gross proceeds from the offering, before deducting underwriting
discounts and commissions and other offering expenses payable
by Gossamer Bio, are expected to be $276.0 million. The
offering is expected to close on February 12, 2019, subject to
satisfaction of customary closing conditions. In addition,
Gossamer Bio has granted the underwriters a 30-day option to
purchase up to an additional 2,587,500 shares of common stock at
the initial public offering price, less underwriting discounts and
commissions.
BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI are
acting as joint book-running managers for the offering.
Registration statements relating to the shares being sold in
this offering have been filed with the Securities and Exchange
Commission and became effective on February 7, 2019. The
offering will be made only by means of a prospectus. Copies of the
prospectus may be obtained from BofA Merrill Lynch,
NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC
28255-0001, Attention: Prospectus Department, or by email at
dg.prospectus_requests@baml.com; or from SVB Leerink, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, or by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com; or from
Barclays, c/o Broadridge Financial Solutions, Attn: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (888) 603-5847, or by email at
barclaysprospectus@broadridge.com; or from Evercore ISI, Attention:
Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York,
NY 10055, or by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190207005935/en/
Gossamer Bio:For Investors:Argot PartnersKimberly
MinarovichTel 212.600.1902kimberly@argotpartners.com
For Media:Argot PartnersDavid
RosenTel 212.600.1902david.rosen@argotpartners.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Jul 2023 to Jul 2024